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Current knowledge is insufficient to explain why only a proportion of individuals exposed to environmental
carcinogens or carrying a genetic predisposition to cancer develop disease. Clearly, other factors must be
important, and one such element that has recently received attention is the human microbiome, the residen-
tial microbes including Bacteria, Archaea, Eukaryotes, and viruses that colonize humans. Here, we review
principles and paradigms of microbiome-related malignancy, as illustrated by three specific microbial-
host interactions. We review the effects of the microbiota on local and adjacent neoplasia, present the estro-
bolome model of distant effects, and discuss the complex interactions with a latent virus leading to malig-
nancy. These are separate facets of a complex biology interfacing all the microbial species we harbor
from birth onward toward early reproductive success and eventual senescence.Introduction
Cancer, which manifests as the uncontrolled proliferation of host
cells, is a leading cause of death in human societies worldwide.
Disease and death result from local and distant spread of malig-
nant cells, as well as from their metabolic and systemic effects.
Although virtually all human tissues containing cells with repli-
cating potential may be affected by cancer, there is host popula-
tion specificity in the timing and tissues involved, in histology,
and in natural history. While many genetic predispositions to
increased cancer risk in general and to the development of spe-
cific malignancies have been identified, environmental effects
dominate for virtually all of the major human cancers (Lichten-
stein et al., 2000).
Significant exposures to environmental carcinogens, in-
cluding toxic chemicals, ionizing radiation, and microbial
pathogens, are extremely varied (Schottenfeld and Fraumeni,
2006). However, current knowledge is insufficient to explain
why only a proportion of heavy smokers develop lung cancer,
or who among those with hepatitis B infections will develop
hepatomas. Clearly, other environmental factors must be
important (Wynder and Gori, 1977), and one such element
that has received attention more recently is the human
microbiome.
Since their earliest origins (Ley et al., 2008a), animals have
been colonized by residential micro-organisms, including bac-
teria, fungi, protozoa, and viruses, that are collectively described
as the microbiome (Lederberg and McCray, 2001). With the
development of new scientific tools, there has been increasing
interest in the composition, function, stability, and host speci-
ficity of the microbiome, and the aggregate of its genes, the
metagenome (Benson et al., 2010; Ley et al., 2006; Li et al.,
2008). This review focuses on the relationships of the micro-
biome to human malignancy. We present general principles
and explore three models of microbiome constituents affecting
cancer risk and pathogenesis. The three paradigms we describe
here illustrate different aspects of the emerging pathogenetic
processes involving the microbiome.324 Cell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc.General Principles
The Microbiome
Humans are colonized by residential microbes including
Bacteria, Archaea, Eukaryotes, and viruses (Turnbaugh et al.,
2007). The proportion of bacterial cells represented in the human
body is estimated to be 90%, and of all genes, >99%. Initial
colonization occurs at the time of birth, and we progressively
acquire a population of 1014 bacterial cells at equilibrium,
which essentially remain for life, and this process is recapitulated
in every human lifetime. A human virome consisting of persistent
colonizing viruses also exists, but is far less explored. Prelimi-
nary examination of the fecal virome has shown numerous
bacteriophages, but with no obvious relationship to neoplasia
(Reyes et al., 2010).
Each anatomical niche possesses its ownmixture of microbial
populations. Although generally conserved at higher taxonomic
levels and in functional properties (Arumugam et al., 2011)
between all humans, interindividual microbiota variation at lower
levels (genus, species, and strain) is enormous (Qin et al., 2010).
The microbiome composition appears to evolve over the human
life span, but the exact magnitude of such changes is unknown.
The individual organisms and cells in the microbiome both com-
pete and cooperate with one another (Blaser and Kirschner,
2007), and the metagenome has both functional and genetic
plasticity (Arumugam et al., 2011; Muegge et al., 2011).
Interactions with Hosts
We do not carry our microbial load passively. There is increasing
evidence for a rich, complex, dynamic, and individual-specific
microbial interaction with hosts. Interactions involve microbial
signaling of host cells that affect metabolic, neurological, in-
flammatory, immunologic, and host-defense functions, among
others (Barton et al., 2007; Dethlefsen et al., 2007; Ley et al.,
2008b; Muegge et al., 2011). The nature of host responses
also shapes microbiome populations and metabolism (Vijay-
Kumar et al., 2010). Indeed, a long-term, well-choreographed
Nash equilibrium may model host-microbial coevolution (Blaser
and Kirschner, 2007). The range of equilibrium arrangements is
Figure 1. Equilibrium between Coevolved
Microbes and Host Cells
(A) Single organism equilibrium. In this model, there is
a counter-regulatory (negative feedback) interaction in-
volving metabolic and physical signals between microbe
and host.
(B) Multiple organisms in equilibrium. In this much more
complex system, organisms may have individual equilib-
rium relationships (e.g., i and ii) with host cells as in (A).
However, the interaction between these two microbes (iii)
will affect their individual interactions. Similarly, another
microbe (iv) might interact exclusively with an organism (i),
but not with the host, with the extent of the interaction
affecting the equilibrium relationships. An alternative is
that an interactive microbe (i) can interact with a second
microbe (v) that directly signals the host, but does not receive direct host signals back. Finally, the host might have a specific interaction with another microbe
(shown as vi), which can have a unidirectional interaction with microbes (e.g., with organism i) but not directly with the host.
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actions with the microbiome are both local, e.g., in the gastroin-
testinal tract lumen, or distant, involving hormonal intermediates,
microbial metabolites, and immunologic messengers.
Human cancers must be considered against the background
of host-microbiome interactions. In general, cancers are log
linear with host age (Nordling, 1953). Three questions are rele-
vant to this review: How are cancers initiated? Why do some
but not all tumors progress? What determines susceptibility to
treatment? In summary, there is a theoretical basis for the micro-
biome to participate in each of these phenomena (Figure 2). For
example, microbiome-induced recruitment of lamina propria
innate and adaptive immune effectors induces epithelial cell
proliferation (Israel et al., 2001), and cell proliferation per se is
pro-oncogenic (Ames and Gold, 1990). Microbial adjuvancy or
suppression affects immune surveillance (Gaboriau-Routhiau
et al., 2009; Ivanov et al., 2009), which limits tumor progression.
Differing drug metabolism affects susceptibility to chemo-
therapy (Wallace et al., 2010).
We are living at a time of great ecological change: global warm-
ing at themacro level and ‘‘disappearingmicrobiota’’ at themicro
level (Blaser and Falkow, 2009). Thus, long-established human-
microbial ecological relationships and their contribution tocancer risk are changing. For example, in developed countries,
the incidence of gastric cancer is falling, whereas esophageal
adenocarcinoma is rising (see below). Nevertheless, several
different types of cancer development can be considered
(Figure 3) at the crossroads of our ancient and our ‘‘postmodern’’
microbiota. Of the microbe-induced human malignancies, Class
A is defined as involving immunologic tissues, Class B requires
direct microbial interactions with parenchymal cells, and Class
C involves distant effects from local interactions. Several exam-
ples (Table 1) may provide a model for not-yet-recognized rela-
tionships between microbiome and particular cancers (Blaser,
2008). We illustrate general types of relationships between
different constituents of the human microbiome and several
human cancers through the following paradigms.
Paradigm 1: Active Inflammation Promoting Cancer
in a Lumenal Organ
H. pylori are microaerophilic, highly motile, curved gram-
negative bacilli that colonize the human stomach (Atherton
and Blaser, 2009). Considerable evidence reveals that H. pylori
is ancestral in humans, colonizing our ancestors before the
major out-of-Africa migration 58,000 years ago (Linz et al.,
2007). Acquired in early childhood and carried for nearly all ofFigure 2. Mechanisms by which the Microbiome
Can Enhance Malignant Transformation and
Cancer Spread
Cancer involves the transformation of physiologically
responsive cells into autonomously replicating tumors that
have the capacity to invade local tissues or spread widely.
Multiple host processes (indicated on the left) govern the
success of neoplastic cells to cause cancer. However, the
interaction of the microbiome with the host (right) yields
effects that can enhance or suppress tumorigenesis.
Microbiome-induced inflammation affects the initiation
(‘‘EARLY’’) of cancers. Medium-term interactions affect
multiple facets that influence whether or not tumors
progress and, if so, in which ways. Finally, ‘‘LATE’’ inter-
actions affect the susceptibility of the tumor to therapies.
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Figure 3. Classification of Microbiome-
Associated Human Malignancies
Three types of relationships can be envisaged between
themicrobiome andmechanisms that give rise of cancers.
In Class A, the primary interactions involve immunocytes;
in Class B, local parenchymal cells; and in Class C, the
local interactions produce distant effects. Specific ex-
amples of all three classes are indicated in Table 1.
Adapted from Blaser (2008) with permission.
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which it was studied (Bardhan, 1997). Also, examination of
gastric 16S rRNA genes indicates that H. pylori dominates the
gastric microbiota (Andersson et al., 2008; Bik et al., 2006).
Thus, H. pylori has been the ancient, dominant, and highly inter-
active member of the human gastric microbiota. Nevertheless,
H. pylori prevalence has steadily decreased over the course of
the 20th century (Chen and Blaser, 2008; Roosendaal et al.,
1997); this is both a major and surprising shift in human
microecology.
As such, we can now measure the consequences of carrying
H. pylori or not. As discussed below, the presence or absence
of the organism can lead to very different gastric physiologies,
and each of the three classes of microbe-induced malignancies
outlined in Figure 3 can be attributed to the presence or absenceTable 1. Examples of Microbe-Induced Human Malignancies by Class
Microbe(s)
Examples of Malignancies by Class
A B
EBVa Lymphomas Nasopharyngeal carcinom
HTLV-1 ATL
HHV-8 Kaposi’s sarcoma
HIV Lymphomas Kaposi’s sarcoma
Hepatitis B Hepatocellular carcinoma
Hepatitis C Lymphomas Hepatocellular carcinoma
H. pyloria MALT gastric lymphoma Gastric adenocarcinoma
HPV Anogenital carcinomas,
oropharyngeal carcinoma
Schistosomal species Bladder cancer
Liver flukes Cholangiocarcinoma
Hypothesized scenarios: microbiome
DMicrobiomec
Microbiome g Colon adenocarcinoma
Abbreviations: ATL, adult T cell leukemia/lymphoma; HHV-8, human herpesvirus 8; HTLV-1, hu
associated lymphoid tissue. Adapted from Blaser (2008) with permission.
a Represents microbes that are constituents of the ancestral human microbiome.
b Brackets indicate that the presence of a specific microbe (e.g. H. pylori) or as yet unidentifi
promote the development of the bracketed malignancy.
c In addition to metabolic activities of usual microbial constituents, changes (D) in the microbi
326 Cell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc.of H. pylori. Substantial epidemiologic, histo-
logic, and experimental animal studies implicate
H. pylori in the causation of gastric adenocarci-
noma (Peek and Blaser, 2002), the second
leading cause of cancer death worldwide (Class
B relationship). In addition, H. pylori is strongly
associated with gastric MALT-lymphomas (Par-sonnet et al., 1994) (Class A relationship). Conversely, H. pylori
has an inverse association with esophageal (gastro-esophageal
junction) adenocarcinoma, consistent with a protective effect
(Islami and Kamangar, 2008) (Class C relationship).
Gastric Cancer
Via secreted substances, physical attachment, and the injection
by a type IV secretion system (TFSS) of its own constituents,
H. pylori are highly interactive with host cells (Odenbreit et al.,
2000), consistent with the Class B model (Figure 3). A major in-
jected constituent is the128 kDa CagA protein, which contains
several tyrosine phosphorylation (EPIYA) domains that are
recognized by host cell kinases, which convert CagA into
p-CagA (Backert and Selbach, 2008). As an indication of
H. pylori complexity, the EPIYA-rich encoding region containsC
a
[Esophageal adenocarcinoma]b
f ½Breast and endometrial adenocarcinomas½Testicular and prostate adenocarcinomas
man T cell lymphotropic virus type 1; MALT, mucosa-
ed member(s) of the microbiome may either inhibit or
ome also may be involved in inducing some cancers.
Figure 4. Multi-Decade Development of Gastric Adenocarcinoma Initiated by H. pylori: Ecologic Model
(A–D) The equilibrium relationship of H. pylori and its host involves recruitment of a population of immune and inflammatory cells in the gastric lamina propria (A).
Over time (decades), the conjunction of the organism and its host response results in continued injury to the epitheliumwith progressive loss of normal architecture
and function (B). This leads to the development of atrophic gastritis (C), with permanently altered architecture, and a reduction in acid secretory function. With
hypochlorhydria, the gastric niche now is dominated by competing microbiome members that have pathogenic properties leading to further inflammation and
tissue injury (D). Over this decades-long (essentially lifelong) progression,H. pylori bacterial populations gradually decline. In the final stage, theH. pylori-induced
atrophic gastritis lowers gastric acidity, which then is a reduced barrier to the intrusion of adventitious pathogenic oropharyngeal and intestinal bacteria.
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EPIYA site number. Strains with C- or D-type EPIYAs signal
host epithelial cells via the Src/Shp-2/MAPK pathway, whereas
EPIYA lacking proteins signal through gp130/JAK/STAT3 (Lee
et al., 2010). Since these are cross-inhibitory pathways, the pop-
ulation biology of H. pylori within a particular locale determines,
with very fine tuning, the nature of host responses, enabling
persistence, but also leading to tissue responses and injury. Indi-
viduals carrying H. pylori strains that possess CagA are at in-
creased risk for the development of precursor lesions for gastric
cancer (i.e., atrophic gastritis and intestinal metaplasia) and
therefore the cancer itself. Multiple signaling pathways may be
involved, since particular alleles ofH. pylori genes are associated
with increased risk of cancer development (Batista et al., 2011).
Particular host polymorphisms that relate to innate immunity
(e.g., affecting IL-1, IL-1RA, and TNF-a expression) enhance
the risk of gastric cancer associated with H. pylori positivity (El-
Omar et al., 2001, 2003; Figueiredoet al., 2002).H.pylori-induced
gastric inflammation recruits stem cells from the bone marrow,
which may also participate in tumorigenesis (Houghton et al.,
2004). The traditional model of gastric carcinogenesis focuses
on host, strain, or interaction differences in explaining H. pylori-
induced gastric adenocarcinoma (Peek and Blaser, 2002). An
alternative model is shown in Figure 4 in which the H. pylori-
host interaction causes progressive degradation of the gastric
niche over decades, H. pylori is essentially lost (Karnes et al.,
1991), and the changes lead to the success of new competing
microbiome populations that are cancer promoting.
Gastric Lymphoma
The presence of H. pylori is strongly associated with primary
gastric lymphoma (Parsonnet et al., 1994; Wotherspoon et al.,
1993). The presence of H. pylori is important in the proliferation
of the tumors, since when H. pylori is eliminated, they often
regress (Yamamoto et al., 2008; Zullo et al., 2010). The tumors
are clonal, but a spectrum encompassing benign polyclonal
lymphoid expansion, emergence of a dominant clone, and
malignant transformation of the clone can be observed (Thiede
et al., 2001). This scenario is consistent with the Class A model
for microbiome-mediated hematopoietic and lymphoid malig-
nancies as outlined in Figure 3.Esophageal Adenocarcinoma
The incidence of GE junction adenocarcinomas (namely esoph-
ageal adenocarcinoma [EAC] and gastric cardia adenocarci-
noma) is rapidly rising in Western countries (Devesa et al.,
1998) just as H. pylori is disappearing (Chen and Blaser, 2008;
Roosendaal et al., 1997). The development of these cancers
(and those on the gastric cardia side of the GE junction) follows
gastro-esophageal reflux disease (GERD) and its metaplastic
sequela (Barrett’s esophagus). The presence of H. pylori, espe-
cially cagA+ strains, is inversely associated with all three lesions
(Peek and Blaser, 2002). These findings have been confirmed
(Islami and Kamangar, 2008) and are consistent with the hypoth-
esis that a change in the gastric microbiome resulting from the
absence of H. pylori is contributing to this epidemic of GE junc-
tion adenocarcinomas. This is biologically plausible based on
emerging trends and on the knowledge that loss of these highly
interactive (especially cagA+) organisms changes gastric physi-
ology, affecting acid secretion (Moss et al., 1992), hormone inter-
actions (Francois et al., 2008, 2011), and T cell populations (Rob-
inson et al., 2008). Further, the loss ofH. pylori is associated with
changes in the composition of the gastric microbiome involving
many other microbial taxa (Maldonado-Contreras et al., 2011).
That change in the microbiome in one location (gastric) may
affect cancer risk in an adjacent, but separate, compartment
(distal esophagus) suggests an important paradigm for other
cancers: the causal agents need not be residents of the affected
tissues (Figure 3, Class C). Nevertheless, there is an esophageal
microbiota (Pei et al., 2004) that is clearly perturbed in pre-
malignant lesions of the esophagus (Yang et al., 2009). Whether
this is cause or effect is uncertain at present but is a promising
area for exploration.
Paradigm 2: Metabolic Effects of Residential Organisms
Leading to Distant Malignancies
The Human Estrobolome
Wepostulate that an important contribution of the human gut mi-
crobiota to host physiology is a functional estrobolome, the ag-
gregate of enteric bacterial genes whose products are capable
of metabolizing estrogens. Especially important are bacterial
species possessing b-glucuronidases and b-glucuronides, en-
zymes involved in estrogen deconjugation and conjugationCell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc. 327
Figure 5. The Estrobolome and Its Switch
Estrogens are steroid hormones derived from the step-
wise reduction of C21 cholesterol. The ovaries are the only
organs capable of full C21 (cholesterol)/ C18 (estrogen)
synthesis; at all other sites of estrogen synthesis (e.g.,
adrenals, adipose tissue), the availability of C19 andro-
gens as substrates and aromatase are limiting factors.
Estrogens circulate in the bloodstream free or protein
bound and are conjugated or unconjugated molecules
that may enter target tissues or be eliminated by the
kidneys. Circulating estrogens undergo Phase I hepatic
metabolism. In the liver, estrogens and their resultant
estrogen metabolites (EMs) then may be conjugated
through methylation, glucuronidation, or sulfonation re-
actions. Conjugated estrogens are subject to biliary ex-
cretion. The estrobolome, the aggregate of enteric bac-
terial genes whose products are capable of metabolizing
estrogens, acts on conjugated estrogens and estrogen
metabolites with downstream physiologic effects. An es-
trobolome enriched in genes encoding enzymes favoring
deconjugation promotes reabsorption of free estrogens
that contribute to the host’s total estrogen burden. Sup-
pression of deconjugation, which may follow antibiotic
exposure, leads to increased estrogen excretion (Martin
et al., 1975). Estrobolomes varying in functional activity
lead to different host-estrogen equilibria via enterohepatic
circulation of varied proportions of conjugated to uncon-
jugated estrogens. The composition of the estrobolome
can be modulated by host-specific and/or environmental
drivers (e.g., antibiotics) exerting selective pressure on its
parental bacterial populations. Shown here for illustration is the ratio of 2-OH/16-OH hydroxylated EMs, which may serve as urinary or serum markers of risk for
certain estrogen related cancers (Bradlow et al., 1995; Gupta et al., 1998; Kabat et al., 1997; Meilahn et al., 1998; Muti et al., 2000)
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et al., 2011; McBain and Macfarlane, 1998). The estrobolome is
predicted to impact endogenous estrogenmetabolism bymodu-
lating the enterohepatic circulation of estrogens, thus affecting
circulating and excreted estrogen levels (Figure 5). A woman’s
lifetime burden of estrogen exposure may reflect in part the
metabolic functioning of her estrobolome. An estrobolome en-
riched in gene products promoting estrogenmetabolite deconju-
gation reactions may result in greater reabsorption of free estro-
gens. Estrobolome variation in levels of functional deconjugative
ability may thus influence development of estrogen-driven neo-
plasia (Figure 3, Class C).
Estrogens and Estrogen-Driven Cancer
Estrogens, steroid hormones derived from the progressive
reduction of C21 cholesterol, may act locally (intracrine function)
or circulate to exert effects on target organs (endocrine function).
The three major forms of endogenous estrogen, estradiol (E2,
dominant during reproductive years), estrone (E1, dominant after
menopause), and estriol (E3, dominant during pregnancy), are
four-ring C18 molecules. Estrogens appear in circulation as
free or protein-bound entities and in both conjugated and uncon-
jugated states. Estrogen exposure begins prenatally and is life-
long. The multiple beneficial effects (cardiovascular, metabolic,
bone, fertility, cognition) contrast with roles in estrogen-driven
cancers. Women with the highest circulating estrogen levels
are at increased risk for developing postmenopausal endome-
trial (Lukanova et al., 2004) and breast cancers (Hankinson
et al., 1998; Kaaks et al., 2005; Key et al., 2002; Lukanova
et al., 2004; Toniolo et al., 1995; Woolcott et al., 2010). Estrogen
metabolism varies between women, with the full physiologic
repertoire of its metabolites being unknown. Estrogens and
estrogen-like molecules classically exert their cellular effects328 Cell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc.by binding to and activating estrogen receptors, although other
receptor-independent mechanisms do exist.
Healthy and Cancerous Cells Express Receptors
for Estrogen
The two recognized estrogen receptors (ERa, ERb) are homolo-
gous ligand-modulated transcription factors. Both are present in
many healthy tissues (including breast, ovary, testis, prostate,
bone, brain, and vascular system) and in certain cancers of the
breast, endometrium, prostate, bone, and lung (Kuiper et al.,
1996). Ligands other than E2, E1, and E3 can bind with varying
affinities to both ERa and ERb (Kuiper et al., 1998) with activation
increasing or repressing host cell transcription with consequent
biologic activity (Jeyakumar et al., 2011). The centrality of es-
trogen to malignancy is reflected in therapeutic interventions
that target estrogen receptor signaling, including the selective
estrogen receptor antagonists (SERMs), widely used to treat
ER(a)-receptor-expressing breast cancer.
Hepatic Estrogen Metabolism and the Enterohepatic
Circulation of Estrogens
Both E1 and E2 undergo Phase I oxidative hepatic metabolism,
leading to the formation of catechol estrogens (e.g., 2-OH,
4-OH, and 16-OH estrogens) (Yager et al., 2009) that then are
conjugated or transformed to semiquinones, which have been
implicated in oncogenesis (Cavalieri et al., 2006). The ratio of
circulating and urinary 2-OH to 16-OH estrogen pathway metab-
olites may be a marker of breast and endometrial cancer risk
(Bradlow et al., 1995; Gupta et al., 1998; Kabat et al., 1997; Mei-
lahn et al., 1998; Muti et al., 2000) . Phase II hepatic conjugation
reactions include methylation via catechol-O-methyltransferase,
glucuronidation via uridine 50-diphospho-glucuronosyltransfer-
ase, and sulfonation via sulphotransferase (Raftogianis et al.,
2000). Somemethylated estrogens, such as 2-methoxyestradiol,
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ities (Lakhani et al., 2003) and are currently being studied as anti-
cancer agents. Conjugated estrogens are not important ligands
for the estrogen receptors (Raftogianis et al., 2000) and are
subject to biliary excretion (Adlercreutz and Martin, 1980; Sand-
berg and Slaunwhite, 1957). Most importantly, there is an enter-
ohepatic circulation of estrogens (Figure 5) with repeated recir-
culation circuits (Adlercreutz, 1962; Sandberg and Slaunwhite,
1957). Recent refinements in analytic methodologies now permit
accurate measurements of conjugated and unconjugated estro-
gens and estrogen metabolites in serum and urine (Ziegler et al.,
2010) and should stimulate investigations of estrogen metabo-
lism in malignancies.
Estrogen Metabolism Requires a Functional
Estrobolome
Gut microbial functions driving estrogen metabolism and con-
tributing to the proportions of recirculated and excreted estro-
gens and estrogen metabolites have long been considered
(Adlercreutz and Ja¨rvenpa¨a¨, 1982; Eriksson, 1970). Reduction
in populations of specific gut bacteria in humans, as occurs
with exposure to antibiotics, causes increased fecal excretion
of conjugated estrogens and decreases in urinary estrogens
(Martin et al., 1975), highlighting the modulatory role of the gut
microbiome’s deconjugating machinery (Adlercreutz and Ja¨r-
venpa¨a¨, 1982; Adlercreutz et al., 1978, 1979; Martin et al.,
1975). Human fecal extracts metabolize estrogens ex vivo, as
would be expected of the estrobolome. The reactions include
reduction, oxidation, and the generation of E2 from E1 as well
as from estradiol 3-glucuronide, E1 from E2 and from estrone
3-sulfate, and E3 from 16a-hydroxyestrone (Lombardi et al.,
1978). Similarly, in vitro incubation of E1, E2, and 16a-hydroxyes-
trone with human feces leads to the interconversion of E1 and E2
and the reduction of 16a-hydroxyestrone to E3, 16-oxoestradiol
to 16-epiestriol, and 15a-hydroxyestrone to 15a-hydroxyestra-
diol (Ja¨rvenpa¨a¨ et al., 1980). Finally, germ-free mice provide
additional evidence for the centrality of host-microbe interac-
tions in estrogen metabolism (Shimizu et al., 1998).
Interventions that Target the Estrobolome Affect
Estrogens
Bacterial composition of the human estrobolome likely reflects
host factors, such as delivery mode at birth, as well as lifetime
environmental influences, including antibiotic use and dietary
composition. Vegetarians have increased fecal excretion of
conjugated estrogens (Goldin et al., 1982; Gorbach and Goldin,
1987), and dietary manipulations affect overall gut microbiome
composition and function (Turnbaugh et al., 2009; Faith et al.,
2011; Muegge et al., 2011). Such pressures exerted over time
on the bacterial communities that constitute the estrobolome
may lead to emergence of functionally distinct patterns, analo-
gous to the broader categorization of the gut phylogenetic enter-
otypes (Arumugam et al., 2011). The confluence of both genetic
and environmental modulators may shape estrobolome func-
tionality that affects cancer risk (Figure 5); as such, estrobolome
analysis could be harnessed to reduce emergence of estrogen-
driven malignancies, such as Type I (endometrioid) endometrial
cancer, estrogen receptor-positive breast cancer, and some
ovarian cancers. Interventions that modify the bacterial con-
stituents of the estrobolome also could modulate functional
activity. Manipulations that specifically target species withb-glucuronidase and b-glucuronide activities could aid in
reducing estrogen-related cancer risk. Changing bacterial popu-
lations to diminish hydroxylation and reductive functions can be
accomplished with of antimicrobial agents, prebiotics, or probi-
otics. If such interventions proved successful, estrobolome
status might inform future risk of malignancy, and measures
could target restoration andmaintenance of a ‘‘healthy’’ estrobo-
lome for that host.
Paradigm 3: Abrogation of Clinical Latency Leading
to Malignant Outcomes
Epstein-Barr Virus
Epstein-Barr virus (EBV) is an ancient (Lacoste et al., 2010;
McGeoch et al., 1995), ubiquitous, and persistent virus that obli-
gately infects humans, leading to lifelong latency. By adulthood,
nearly all humans have acquired EBV (Henle et al., 1969). As
such, EBV should be considered part of the human virome,
and it is with this premise that we discuss EBV and associated
malignancies in this review.
EBV is a 172 kb, double-stranded DNA virus of the g-herpes-
virus subfamily of Lymphocryptovirus, present as a characteristic
(Penkert and Kalejta, 2011) circular episome within the human
memory B-lymphocyte nucleus (Niederman et al., 1970). EBV
is associated with relatively low short-term cost and even
possible benefit to the host (Barton et al., 2007), but harbors
long-term malignant potential. The emergence of an EBV-
associated cancer, often decades after EBV acquisition, reflects
complex interactions between the virus and its host that culmi-
nate in the loss of latency and highlight how a nearly universal
member of our commensal microbiota contributes to malig-
nancy. In hosts who develop Burkitt’s lymphoma, posttransplan-
tation lymphoproliferative disorders (PTLD), or nasopharyngeal
carcinoma (NC), EBV has a biphasic life cycle. However, most
EBV-positive individuals do not develop EBV-associated can-
cers, but instead just harbor latent virus. EBV’s presence is
thus necessary but not sufficient for the emergence of an EBV-
associated malignancy.
Interactions of Epstein-Barr Virus with Its Human Host
EBV is transmitted between humans through saliva. Children
become susceptible to EBV transmission after maternal anti-
body protection wanes; infection is either asymptomatic or
may lead to nonspecific symptoms. EBV acquisition in adoles-
cence or in young adulthood, as seen in Western societies,
results in illness termed infectious mononucleosis (IM) in about
half of the infected individuals. The intensity of the host’s T cell
responses to primary EBV is responsible for this acute illness
(Callan et al., 1996).
After the initial replicative lytic phase, EBV undergoes a shift to
one of a series of tightly regulated latency states, each character-
ized by transcriptional repression to evade immune surveillance
(Figure 6). Differential regulation of promoter utilization underlies
EBV latency gene expression, possibly involving chromatin insu-
lator protein (Tempera et al., 2011). Compared to the >80 genes
expressed in the lytic cycle, in a Latency III program EBV princi-
pally expresses six nuclear antigens (EBNAs) and all three inte-
gral latent membrane proteins (LMPs), whereas in Latency II
only EBNA1 and LMP1 and 2 are expressed, and in Latency I
only EBNA1 is expressed (Figure 6). EBNA1 is crucial for EBV
episome replication and maintenance, and Latency I representsCell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc. 329
Figure 6. Schematic of EBV-Host Interactions
(A) EBV (teal virions with black tip) is acquired orally and
targets B cells (lavender nucleated circles) and permissive
epithelial cells of the oral pharynx (green). The major EBV
envelope glycoproteins gp350 and gp220 (black tip)
interact with complement receptor CD21 (brown) on the
surface of naive resting B lymphocytes, leading to viral
binding. Additional EBV B cell interactions involving fusion
proteins and HLA class II molecules (not shown) lead to
virus-cell fusion and EBV internalization. EBV bound to the
B cell surface likely allows for its transfer to oropharyngeal
epithelial cells. The initial lytic viral reproductive phase
may be asymptomatic (usually) or may manifest clinical
symptoms and is termed infectious mononucleosis (IM).
During the lytic phase, virus is shed via the saliva and can
infect naive hosts.
(B) After the initial lytic phase, EBV evades host im-
munosurveillance to achieve persistence though ‘‘trans-
lational latency,’’ the tightly regulated selective expression
of viral latent proteins and of noncoding RNAs. The former
include six Epstein-Barr virus nuclear antigens (EBNAs)
(1, 2, 3A, 3B, 3C, and LP) and three integral latent
membrane proteins (LMPs) (1, 2A, and 2B). The latter
include EBERs (1 and 2), small noncoding RNAs abun-
dantly expressed in latently infected EBV cells, as well as
multiple microRNAs that contribute to EBV-associated
cellular transformation. EBV miRNAs are encoded by two
transcripts (in the BART and BHRF1 loci). Three distinct
‘‘transitional’’ EBV latency programs (Latency I, II, and III)
are characterized by specific gene expression profiles that
allow for establishing latency and enhancing cell survival
and proliferation. After the initial lytic phase, EBV replicates as an episome in tandem with the host cell genome. EBV employs host cell-driven DNA genomic
methylation and modulation of NFkB activity and Notch signaling pathway manipulations (not shown) to establish true latency (Latency 0) in resting memory B
cells (purple circles), with highly restricted EBV gene expression. Nonpathogenic and invisible to the host immune system, Latency 0 EBV persistently populates
memory B lymphocytes. In the course of the latently infected hosts’ life, episodic disruptions of latency occur (depicted as ‘‘STRESS’’ and yellow bolt), resulting in
EBV replication and viral shedding with potential spread to other hosts. Latent EBV also can contribute to several cancers (dashed line), including lymphomas
such as Burkitt’s lymphoma (BL) and nasopharyngeal carcinoma (NPC). Exogenous immunosuppression may result in posttransplantation lymphoproliferative
disorders (PTLD). The emergence of malignancy appears to require interactions of cofactors, for example P. falciparum in BL, and individual host characteristics,
including HLA type in NPC.
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‘‘Latency 0’’ in which there is no viral antigen expression is postu-
lated to occur in vivo, consistent with the lifelong persistence of
the EBV genome in memory B cells in healthy hosts (Babcock
et al., 1998; Miyashita et al., 1995). Even in latency, EBV is capa-
ble of regulating B cell protein expression and proliferation, and
the viral genome can replicate as an episome, in tandem with
host cell division.
EBV Manipulates Host Innate Immune Signaling
Pathways
EBV exploits fundamental host innate signaling pathways, in-
cluding NFkB, TNF-a, and Notch receptor pathways, throughout
its life cycle. It does so to its advantage, beginning when viral
envelope glycoprotein (gp350/220) binds to host B cell surface
CD21 and TLR2, leading to persistent NFkB classical pathway
activation (Gaudreault et al., 2007). Later, EBVachieves immortal-
ization via activation of both the alternative and classical NFkB
pathways (Kung and Raab-Traub, 2010; Mosialos et al., 1995;
Song andKang, 2010). EBV is able to convert host B lymphocytes
into lymphoblastoid cell lines by expressing EBV nuclear and
membrane proteins, EBNAs, and LMPs (in Latency III) that regu-
late transcription through the Notch and TNF-a receptor path-
ways (Cahir-McFarland et al., 2004). EBV is able to reroute the
TNF receptor family signaling pathway (Izumi and Kieff, 1997;
Le Clorennec et al., 2008; Liebowitz, 1998; Mosialos et al., 1995).
Such interactions favor EBV persistence, yet EBV latency may
also provide mutualistic benefit to its hosts as an immune330 Cell Host & Microbe 10, October 20, 2011 ª2011 Elsevier Inc.adjuvant (White et al., 2010), protecting against lethal Listeria
monocytogenes and Yersinia pestis infections (Barton et al.,
2007). Over a host’s lifetime, incompletely characterized stimuli
occasionally induce EBV to emerge from latency and initiate
a lytic state via sequential expression of genes responsible for
replication and whole virion assembly. This (generally clinically
silent) replication results in viral shedding and potential spread
to other EBV-naive hosts.
EBV-Associated Cancer as a Consequence
of Persistence
EBV plays a part in neoplastic transformation when latency is
breeched. EBV LMP1 and LMP2A can activate the mTOR,
AKT, and PI3K pathways regulating functions relevant to tumor-
igenesis, including cellular proliferation, growth, survival, and
mobility (Fukuda and Longnecker, 2007; Moody et al., 2005;
Swart et al., 2000), whereas LMP1 miRNA inhibits the tumor
suppressor p53 (Fukuda and Longnecker, 2007; Liu et al.,
2005; Moody et al., 2005; Swart et al., 2000). Signaling of tumor
suppression pathways that initiate cell-cycle arrest and priming
of apoptotic pathways occurs when latency is lost. EBV-associ-
ated neoplasms show three distinct patterns of latency-associ-
ated gene expression (Rowe et al., 1992). Burkitt’s lymphoma
exemplifies the Latency I program in which the Qp promoter-
induced EBNA1 is expressed with small EBV-encoded RNAs
(EBERs) and BamHI-A rightward transcript (BART). Latency II,
characteristic of nasopharyngeal carcinoma (NPC), EBV-posi-
tive Hodgkin’s lymphoma, EBV-positive gastric carcinoma, and
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and Qp promoter-induced EBNA, with added LMP1, 2A, and /or
2B expression (Brooks et al., 1992). PTLDs are associated with
the Latency III program in which all EBV latent gene products
are expressed. EBV Latency III-regulated gene productsmediate
cell migration, antigen presentation, MAP kinase pathway, and
interferon (IFN) signaling (Cahir-McFarland et al., 2004).
Latency I Program: EBV-Associated Burkitt’s
Lymphoma, Exogenous Cofactors, and c-Myc
Burkitt’s lymphoma, a high-grade B cell malignancy, has distinct
clinical-epidemiological variants: endemic (eBL), sporadic (sBL),
andHIV associated (HIVBL). Each of these tumors has reciprocal
chromosomal translocations involving immunoglobulin loci on
chromosomes 14, 22, or 2 and c-myc (MYC) on chromosome 8
(Manolov and Manolova, 1972; Dalla-Favera et al., 1982), but
only eBL tumors incorporate EBV DNA. Typical of Latency I,
only EBNA1 is expressed in eBL, which is the most common
pediatric tumor in Sub-Saharan Africa, where EBV acquisition
occurs very early in life. Its distribution in regions of Africa and
Papua New Guinea, where malaria is holoendemic, has impli-
cated P. falciparum as cofactor, promoting lymphoma through
immunosuppressive effects on EBV-specific T cell immunity
(Njie et al., 2009; Whittle et al., 1984) and B cell proliferation in-
volving P. falciparum erythrocyte membrane protein 1 (PfEMP1)
interactions with host memory B cells harboring latent EBV
(Cheˆne et al., 2007). An alternative mechanism implicates ma-
laria and initial EBV-induced B cell proliferation, with consequent
activation-induced deaminase (AID) dysregulation leading to the
characteristic c-myc translocation and lymphoma (Thorley-
Lawson and Duca, 2007). In that schema, emergence of sBL
reflects spontaneous (non-microbe-driven) c-myc translocation,
whereas in eBL an EBV-driven series of events abetted by
P. falciparum culminates in the characteristic oncogenic c-myc.
Latency II Program: Host HLATypes andEBV-Associated
Nasopharyngeal Carcinoma
EBV is present in epithelial NPC cells, where it establishes
a latency pattern with EBNA1 and either LMP1 or LMP2 protein
expression (Latency II) (Brooks et al., 1992). The highest inci-
dence of NPC is in Southeast China, particularly in Guangxi
Province, where it occurs in association with specific host HLA
haplotypes (Tang et al., 2010). The underlying pathogenesis of
EBV-induced NPC remains obscure.
Latency III Program: Host Immune Suppression
and EBV-Associated PTLD
PTLDs represent heterogeneous diseases that vary from reac-
tive polyclonal B cell hyperplasia to monoclonal tumors to fatal,
aggressive non-Hodgkin’s lymphomas (Penn et al., 1969). PTLD
may occur after hematopoietic stem cell or solid organ trans-
plantation.Most cases of PTLD are of B cell origin and EBV asso-
ciated (Young et al., 1989). Intensive immunosuppressive regi-
mens to avoid graft rejection affect risk for PTLD development.
The highest incidence of PTLD after small bowel transplan-
tation compared to other organs (e.g., kidney) may relate to
the quantity of transplanted lymphoid tissue, with more EBV +
B cell populations (Cohen, 2000). EBV latency becomes disrup-
ted in PTLDs, diseases related to the intersection of 20th century
medical technologies with an ancient virome constituent. PTLD
lesions express EBV Latency III genes, whose encoded proteins
are involved in signal transduction, transcription, and proteincatabolism and in cell motility, shape, and adhesion characteris-
tics (Carter et al., 2002; Delecluse et al., 1995; McKnight et al.,
1994; Rea et al., 1994). Impaired a-EBV T cell function permits
EBV-driven B cell proliferation, resulting in PTLD.
Future Therapies
Hanahan and Weinberg outline ten therapeutic approaches to
target the central functional and enabling pathways involved in
cancer (Hanahan and Weinberg, 2011). We envision that mi-
crobes can be harnessed (Blaser, 1997, 2010) to perform many
of these therapeutic functions. For example, colonization of spe-
cific niches in the gut lumen (stomach, distal esophagus, rectum)
with probiotic bacterial strains capable of modulating local
inflammation and immunity could help control lumenal gastroin-
testinal tract neoplasia. Similarly, establishment and mainte-
nance of an estrobolome (with diminished deconjugation ac-
tivity) that favors estrogen excretion pathways may reduce risk
of developing estrogen-drivenmalignancy. Knowledge of themi-
crobiome can be applied to targeting both specific anatomic
sites and functional capabilities. Members of the human micro-
biota can suppress aspects of cellular immunity (e.g., B. fragilis
[Mazmanian et al., 2008; Round et al., 2011]), whereas others
(e.g., cagA+H. pylori) induce proinflammatory cytokines (Backert
and Selbach, 2008). In the future, we can either beneficially
target particular effector microbes to the desired location or
engineer the desired genes into microbes that naturally colonize
those sites.
Conclusions
The examples provided are not comprehensive, but rather indi-
cate several conserved and paradigmatic mechanisms; micro-
biome constituents likely will have roles in other human cancers
(Garrett et al., 2009; Wu et al., 2009). As recently discussed
(Dominguez-Bello et al., 2011), nature must remove senescent
individuals to liberate resources for younger members of the
same species. A role for our ancient, interactive, residential
microbes in clock-like functions (Blaser, 1997) is intuitive. In
that manner, our residents may be true symbionts, improving
host fitness early in life throughmetabolic and pathogen defense
functions and leading to demise through neoplasia in the postre-
productive period. If the hypothesis that malignancy is part of
mammalian selection is correct, then other human cancers
whose rates are log linear with age will predictably be found to
reflect microbiome-induced pathogenesis.
Finally, the microbiome affects the metabolism of xenobiotics
(Figure 2), such as pharmaceutical agents (Clayton et al., 2009),
including those used to treat cancer. Responses to particular
chemotherapeutic agents have been linked to specific gut mi-
crobiome metabolic activities (Wallace et al., 2010). Better
knowledge of microbiome composition and metabolic activities
will ultimately improve therapeutic choices, with new agents,
dosing regimens, and monitoring strategies. Using such knowl-
edge should improve therapeutic/toxic ratios and represents
another exciting frontier in cancer research.
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